HCP 13
Medical Oncologist · United States · Attending physician
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Confident in the data; ready to adopt and comfortable with the safety management required.
Key themes
Pre / post perception
Overall perception shiftNo matched pre/post perception for this HCP
This conversation is not part of the matched pre/post perception sample, so a before-and-after comparison is not available. Their qualitative positions above still reflect what they said at congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“This is a setting where we badly need options, and this endpoint really moves the needle for me.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“For the right patient the balance clearly favours treating.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“In node-positive patients with higher recurrence risk, the case for treating is strong.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“In selected late recurrences I would still consider continuing the class with modification.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“The data feel mature and robust enough for me to act on confidently.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“The main adverse events are ones we already know how to manage.”